Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.49−0.10 (-6.29%)
Close on Nov 12, 2026Market cap $139.64MP/E –Yield –
Innate Pharma cash
Cash and short-term investments held at the end of each period.
Innate Pharma's cash was €6.46M at Jun 30, 2026. For fiscal 2025 it was €28.09M, down 57.7% from the year before. The highest annual figure on record is €202.89M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €28.09M | -57.7% |
| FY2024 | Dec 31, 2024 | €66.40M | -6.0% |
| FY2023 | Dec 31, 2023 | €70.61M | -16.2% |
| FY2022 | Dec 31, 2022 | €84.23M | -18.8% |
| FY2021 | Dec 31, 2021 | €103.76M | -24.2% |
| FY2020 | Dec 31, 2020 | €136.79M | -32.6% |
| FY2019 | Dec 31, 2019 | €202.89M | +33.2% |
| FY2018 | Dec 31, 2018 | €152.31M | +53.3% |
| FY2017 | Dec 31, 2017 | €99.37M | -43.5% |
| FY2016 | Dec 31, 2016 | €175.91M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €6.46M | -90.8% |
| Q4 FY2025 | Dec 31, 2025 | €28.09M | -60.2% |
| Q2 FY2025 | Jun 30, 2025 | €53.70M | -24.8% |
| Q4 FY2024 | Dec 31, 2024 | €66.40M | -21.2% |
| Q2 FY2024 | Jun 30, 2024 | €69.99M | -32.0% |
| Q4 FY2023 | Dec 31, 2023 | €70.61M | -32.0% |
| Q2 FY2023 | Jun 30, 2023 | €71.41M | -31.3% |
| Q4 FY2022 | Dec 31, 2022 | €84.23M | -38.4% |
| Q2 FY2022 | Jun 30, 2022 | €102.95M | -21.7% |
| Q4 FY2021 | Dec 31, 2021 | €103.76M | -48.9% |
| Q2 FY2021 | Jun 30, 2021 | €103.98M | -31.7% |
| Q4 FY2020 | Dec 31, 2020 | €136.79M | +37.7% |
| Q2 FY2020 | Jun 30, 2020 | €131.54M | -25.2% |
| Q4 FY2019 | Dec 31, 2019 | €202.89M | – |
| Q4 FY2018 | Dec 31, 2018 | €152.31M | – |
| Q4 FY2017 | Dec 31, 2017 | €99.37M | – |
| Q4 FY2016 | Dec 31, 2016 | €175.91M | – |
See a number that looks wrong?